This country approves Ozempic to reduce risk of kidney disease in diabetes patients
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD).
The Times of India ·